TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31126121
Drug: Calcium +
Normalized name: Calcium + D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium + vitamin D supplements (1500 mg/day Ca and 600 IU/day vitamin D)
Study: 31126121
Drug: Placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills (Control)
Study: 26694929
Drug: Control (C)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (C) - sham block with 2 ml normal saline
Study: 24666144
Drug: Functional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional therapy (focused on sleep and daily lifestyle regularity)
Study: 24666144
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (focused on emotional issues, avoiding sleep and lifestyle regularity)
Study: 17889491
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide
Study: 15953714
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (EPO) 10000 IU thrice weekly subcutaneously (n = 211)
Study: 8697548
Drug: 0.5 L
Normalized name: AIR 20.5 L in 100 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 L Ringer's lactate (Group 1)
Study: 8697548
Drug: 1.0 L
Normalized name: NUTREN 1.0 LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 L Ringer's lactate (Group 2)
Study: 6609700
Drug: Piroxicam 20mg
Normalized name: PIROXICAM 20MG CAP
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam 20mg once daily
Study: 6609700
Drug: Ibuprofen 400mg
Normalized name: IBUPROFEN 400MG TAB
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400mg three times a day
Study: 29555497
Drug: Outpatient physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient physical therapy (PT) for 6 weeks
Study: 28011813
Drug: 2-dose MV
Normalized name: MV Neuro
DrugBank: MV-NB-02 (DB17305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose MV
Study: 28011813
Drug: 2-dose MV
Normalized name: MV Neuro
DrugBank: MV-NB-02 (DB17305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose MV with OPV0 in the first week of life
Study: 28011813
Drug: 2-dose MV
Normalized name: MV Neuro
DrugBank: MV-NB-02 (DB17305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose MV with OPV0 after the first month of life
Study: 28011813
Drug: 2-dose MV
Normalized name: MV Neuro
DrugBank: MV-NB-02 (DB17305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose MV without campaign-OPV
Study: 28011813
Drug: 1-dose MV
Normalized name: MV Neuro
DrugBank: MV-NB-02 (DB17305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-dose MV with campaign-OPV before enrolment
Study: 28011813
Drug: 2-dose MV
Normalized name: MV Neuro
DrugBank: MV-NB-02 (DB17305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose MV with campaign-OPV before enrolment
Study: 24803100
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg simvastatin day(-1) with 75 mg clopidogrel day(-1)
Study: 24803100
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg fluvastatin day(-1) with 75 mg clopidogrel day(-1)
Study: 24803100
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg clopidogrel day(-1) alone
Study: 24803100
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg clopidogrel day(-1) with simvastatin
Study: 24803100
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg clopidogrel day(-1) with fluvastatin
Study: 19276396
Drug: Cisplatin 80
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m2 with NVBiv 30 mg/m2 on day 1 and NVBo 80 mg/m2 on day 8 every 3 weeks (arm A)
Study: 19276396
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 and DCT 75 mg/m2 on day 1 every 3 weeks (arm B)
Study: 12150702
Drug: Experimental therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental therapies involving IL-10, transforming growth factor-beta, granulocyte colony-stimulating factor, and IFN-phi
Study: 9638985
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of behenoyl‐cytosine‐arabinoside (BHAC), daunorubicin (DNR), 6‐mercaptopurine (6‐MP) and prednisolone (PSL)
Study: 9638985
Drug: Residual leukemic
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residual leukemic cell counts of less than 300 cells/microl in the bone marrow at the end point of induction therapy
Study: 8074068
Drug: 42 g
Normalized name: PETROLATUM 42 g in 100 g TOPICAL OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42 g fat
Study: 8074068
Drug: 31 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 31 g fat
Study: 29980128
Drug: Inpatient and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient and day hospital treatment
Study: 29980128
Drug: Nonresponse at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonresponse at the end of treatment
Study: 28489240
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injection into the tonsillar capsule during electrical tonsillectomy
Study: 28489240
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection during electrical tonsillectomy
Study: 25589220
Drug: Axitinib 5
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 5 mg single dose
Study: 25589220
Drug: Axitinib 5
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 5 mg single dose with ketoconazole 400 mg once daily
Study: 18460478
Drug: Chitosan 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan 4.5 g per day
Study: 18460478
Drug: Chitosan 6.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan 6.75 g per day
Study: 18460478
Drug: Glucomannan 6.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucomannan 6.75 g per day
Study: 18460478
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g chitosan)
Study: 11818160
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of AVA 4 weeks apart IM
Study: 11818160
Drug: IM administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IM administration of AVA
Study: 11818160
Drug: SQ administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SQ administration of AVA
Study: 11818160
Drug: Longer dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer dose interval between first two doses
Study: 10223393
Drug: Supportive recall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive recall treatments at 3-month intervals
Study: 10223393
Drug: Supportive recall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive recall treatments at 6-month intervals
Study: 10223393
Drug: Supportive recall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive recall treatments at 12-month intervals
Study: 10223393
Drug: Supportive recall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive recall treatments at 18-month intervals
Study: 10223393
Drug: Supportive recall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive recall treatments (all groups)
Study: 7742152
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tablet of 882C87
Study: 7742152
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg i.v. of 882C87
Study: 7742152
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of [14C]-882C87
Study: 2038185
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 1 liter of saline
Study: 7046543
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide and oral azathioprine (Group 2)
Study: 7046543
Drug: Boluses of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boluses of intravenous cyclophosphamide (Group 3)
Study: 31603998
Drug: Transdermal 17β-estradiol
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17β-estradiol patch (PATCH) with 200 mg cyclic oral micronized progesterone
Study: 31603998
Drug: Combined 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 30 μg ethinyl estradiol and 0.15 mg desogestrel pill (PILL)
Study: 31603998
Drug: Transdermal 17β-estradiol
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17β-estradiol patch (PATCH)
Study: 31594740
Drug: Sedative use
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative use
Study: 17786707
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy (chemotherapy-only group)
Study: 12944571
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (methotrexate, vinblastine, doxorubicin, and cisplatin) followed by radical cystectomy
Study: 9690541
Drug: IFN-alpha, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha, 3 x 10(6) IU three times weekly by subcutaneous injection for 36 months or until melanoma recurrence
Study: 7654890
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily followed by no maintenance treatment (OM)
Study: 7654890
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily plus cisapride 5 mg t.d.s. followed by cisapride 5 mg t.d.s. maintenance treatment (OMCIS)
Study: 7654890
Drug: Cisapride 5
Normalized name: cisapride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 5 mg t.d.s. maintenance treatment
Study: 7654890
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily plus cisapride 5 mg t.d.s. (OMCIS)
Study: 26148680
Drug: Phytosterols 2
Normalized name: phytosterols 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterols 2 g
Study: 26148680
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Pravastatin 40 mg and Phytosterols 2 g)
Study: 23177167
Drug: Corticosteroid (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (40 mg triamcinolone)
Study: 23177167
Drug: NSAID (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID (60 mg ketorolac)
Study: 19428882
Drug: MMR and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR and varicella vaccines (separate injections)
Study: 15504187
Drug: 0.4% end‐tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% end‐tidal sevoflurane inhalation
Study: 15504187
Drug: 0.7% end‐tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7% end‐tidal sevoflurane inhalation
Study: 15504187
Drug: 2.0% end‐tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0% end‐tidal sevoflurane inhalation
Study: 11050521
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia started before surgery (12 patients received epidural mepivacaine 20 mg mL(‐1) and morphine perioperatively)
Study: 11050521
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia started after surgery (14 patients received an epidural bolus of bupivacaine 2.5 mg mL(‐1) and morphine after skin closure)
Study: 11050521
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (bupivacaine 2.5 mg mL(‐1) with morphine administered for three postoperative days)
Study: 9493700
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (40 mg sustained-release twice daily)
Study: 2906874
Drug: Ketanserin +
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin + beta-blocker
Study: 2906874
Drug: Ketanserin +
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin + diuretic
Study: 28284557
Drug: Binimetinib 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binimetinib 45 mg orally twice daily
Study: 28284557
Drug: Dacarbazine 1000
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine 1000 mg/m2 intravenously every 3 weeks
Study: 18004988
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg tegaserod bid
Study: 20803855
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg of isobaric bupivacaine with 25 microg of fentanyl and 100 microg of morphine
Study: 20803855
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of isobaric bupivacaine with 25 microg of fentanyl and 100 microg of morphine
Study: 16253158
Drug: Low-dose perindopril
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose perindopril (2 mg/d initially, increased to 2-4 mg/d)
Study: 16253158
Drug: High-dose perindopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose perindopril (2 mg/d initially, increased to 8-10 mg/d)
Study: 12140470
Drug: Topical vitamin
Normalized name: vitamin A Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vitamin K cream applied after laser treatment
Study: 12140470
Drug: Placebo (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle cream) applied after laser treatment
Study: 12140470
Drug: Topical vitamin
Normalized name: vitamin A Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vitamin K cream applied before laser treatment
Study: 12140470
Drug: Placebo (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle cream) applied before laser treatment
Study: 9874863
Drug: EACA (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: EACA (150 mg/kg, i.v. before CPB)
Study: 9874863
Drug: PRP-EACA (PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-EACA (PRP 10 ml/kg harvested with a plasma saver followed by i.v. EACA 150 mg/kg)
Study: 7751850
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and aggressive management of modifiable risk factors
Study: 2658918
Drug: Intravenous ceftriaxone‐metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone‐metronidazole preparation
Study: 47638
Drug: Hydromorphone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (4 mg i.v.)
Study: 47638
Drug: Methadone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (100 mg p.o. daily)
Study: 30885518
Drug: Daily sunscreen
Normalized name: ZINC OXIDE 220 mg in 1 mL TOPICAL CREAM [SPF 30 Daily Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sunscreen use for 4.5 years
Study: 27578624
Drug: Pharmacist-led medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led medication reconciliation and charting service
Study: 23702931
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg MK-4 daily
Study: 17261383
Drug: Interferon alfa-2a
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa-2a treatment for 24 months
Study: 17261383
Drug: Interferon alfa-2a
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa-2a treatment
Study: 9554266
Drug: Nasal OMV
Normalized name: Omvoh
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal OMV vaccine administered as nose drops or nasal spray
Study: 9554266
Drug: Nasal OMV
Normalized name: Omvoh
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal OMV vaccine
Study: 9554266
Drug: Nasal OMV
Normalized name: Omvoh
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal OMV vaccine with whole inactivated influenza virus
Study: 2648723
Drug: Metformin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 0.5 g trice daily for 4 weeks
Study: 25787877
Drug: 4-g ginger
Normalized name: WORMWOOD 0.4 g in 0.4 g / SAFFLOWER 0.4 g in 0.4 g / GINGER 0.4 g in 0.4 g BUCCAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-g ginger supplementation
Study: 24439186
Drug: Alogliptin (ALO,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin (ALO, 25 mg, once daily) as monotherapy
Study: 24439186
Drug: Alogliptin (ALO,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin (ALO, 25 mg, once daily) as add-on to metformin
Study: 24439186
Drug: Alogliptin (ALO,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin (ALO, 25 mg, once daily) as add-on to pioglitazone ± metformin
Study: 24439186
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) as monotherapy
Study: 24439186
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) as add-on to metformin
Study: 24439186
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) as add-on to pioglitazone ± metformin
Study: 19624593
Drug: Butea superba
Normalized name: BUTEA SUPERBA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butea superba (BS) 100 mg
Study: 18257943
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g cocoa powder dissolved in 250 ml whole milk (CC-M)
Study: 18257943
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g cocoa powder dissolved in 250 ml water (CC-W)
Study: 18257943
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml whole milk
Study: 16634954
Drug: Conventional chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chlorhexidine solution (0.2%; CHX)
Study: 16634954
Drug: Chlorhexidine solution
Normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine solution with anti-discolouration system (0.2%, alcohol-free chlorhexidine solution (CSP))
Study: 16634954
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (Pla)
Study: 12372669
Drug: Nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10 to 40 mg/day) with possible addition of enalapril (5 to 20 mg/day) or hydrochlorothiazide (12.5 to 25 mg/day)
Study: 17595475
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac 0.1%
Study: 2184557
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (conventional treatment)
Study: 363773
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of ascorbic acid
Study: 363773
Drug: Lactose capsules
Normalized name: lactose Oral Capsule
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose capsules
Study: 31748982
Drug: Argon plasma
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon plasma treatment (PAT)
Study: 29699758
Drug: sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sildenafil 100 mg
Study: 24837141
Drug: Traditional neuro-developmental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional neuro-developmental physical therapy program without orthotic management (Group A)
Study: 24331774
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment with topical antibiotics
Study: 24331774
Drug: No periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No periodontal treatment (control group)
Study: 16377677
Drug: Posaconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole (200 mg four times a day or 400 mg twice a day)
Study: 12823855
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) plus calcium and vitamin D3
Study: 8292064
Drug: Loratadine syrup
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine syrup (5 or 10 mg QD)
Study: 8292064
Drug: Terfenadine suspension
Normalized name: terfenadine Oral Suspension
DrugBank: Terfenadine (DB00342)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terfenadine suspension (30 mg b.i.d.)
Study: 3492571
Drug: Various serological
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various serological assays of antibody to PRP
Study: 3492571
Drug: Different antigen
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different antigen preparations used in assays
Study: 18760066
Drug: Total Dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Dose Infusion of low molecular weight iron dextran
Study: 18760066
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation (ferrous sulphate 200 mg three times a day)
Study: 11957809
Drug: Recombinantly produced
Normalized name: Recombinate Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinantly produced TNF-α soluble receptor
Study: 4008112
Drug: Propranolol retard
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Avlocardyl Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol retard 160 mg